The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases.
Sten Nilsson
Consultant or Advisory Role - Algeta
Other Remuneration - Bayer
A. Oliver Sartor
Consultant or Advisory Role - Algeta; Bayer
Oyvind S. Bruland
Consultant or Advisory Role - Algeta
Stock Ownership - Algeta
Honoraria - Algeta
Expert Testimony - Algeta (U); Bayer (U)
Other Remuneration - Bayer
Fang Fang
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Anne-Kirsti Aksnes
Employment or Leadership Position - Algeta
Stock Ownership - Algeta
Chris Parker
Consultant or Advisory Role - Algeta; Bayer; BN ImmunoTherapeutics
Honoraria - Amgen; Astellas Pharma; Bayer; Janssen; Sanofi ; Takeda